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DOI 10.1016/j.ccr.2012.05.015SUMMARYGenes mutated in patients with Fanconi anemia (FA) interact with the DNA repair genes BRCA1 and BRCA2/
FANCD1 to suppress tumorigenesis, but the molecular functions ascribed to them cannot fully explain all of
their cellular roles. Here, we show a repair-independent requirement for FA genes, including FANCD2, and
BRCA1 in protecting stalled replication forks from degradation. Fork protection is surprisingly rescued in
FANCD2-deficient cells by elevated RAD51 levels or stabilized RAD51 filaments. Moreover, FANCD2-
mediated fork protection is epistatic with RAD51 functions, revealing an unanticipated fork protection
pathway that connects FA genes to RAD51 and the BRCA1/2 breast cancer suppressors. Collective results
imply a unified molecular mechanism for repair-independent functions of FA, RAD51, and BRCA1/2 proteins
in preventing genomic instability and suppressing tumorigenesis.INTRODUCTION
Replication stalling is central to the mechanism of efficacy
of many commonly used cancer chemotherapeutics. These
include agents that induce DNA lesions, such as camptothecin
and cisplatin, as well as those that stall replication progression
by perturbing the composition and/or concentration of nucleo-
tide pools, such as gemcitabine and 5-fluorouracil (Stathis and
Moore, 2010). Tumor suppressors mutated in Fanconi anemia
(FA) are crucial for preventing genomic instability upon replica-
tion stalling (Moldovan and D’Andrea, 2009), thus providing
a context in which to understand cellular responses to perturbed
DNA replication.
The FA pathway involves monoubiquitination of FANCD2-
FANCI proteins by the FA core complex in addition to a parallel
or downstream function of homologous recombination (HR) pro-
teins, including the breast cancer suppressor BRCA2/FANCD1Significance
Replication stalling is at the heart of many chemotherapeutic ag
DNA (e.g., gemcitabine) and those that block replication fork pr
tion stalling agents activate the FA/BRCA tumor suppressor pa
components. We report here an unexpected function of the FA
nucleolytic degradation. This finding provides a cellular unders
significant implications for ongoing research efforts in unders
resistance, and emerging therapeutic strategies.
106 Cancer Cell 22, 106–116, July 10, 2012 ª2012 Elsevier Inc.(Moldovan and D’Andrea, 2009) (Figure 1A). Together, FA and
HR proteins suppress cellular sensitivity to DNA replication
poisons that induce DNA interstrand crosslinks (ICLs), such
that mechanistic studies have largely focused on the connection
between these proteins in the context of ICL repair. In vitro
studies have demonstrated that FANCD2 promotes break
formation at ICLs and translesion synthesis by an unknown
mechanism, while HR proteins act downstream of ICL process-
ing in repairing the collapsed fork caused by strand breakage
(Long et al., 2011).
Paradoxical to these functions in promoting DNA breakage
and subsequent break repair, the FA/BRCA protein network is
also highly activated by replication stalling from depletion of
nucleotide pools, such as from hydroxyurea (HU), which does
not elicit physical DNA lesions that require removal (Howlett
et al., 2005; Naim and Rosselli, 2009), as well from other lesions
(Langevin et al., 2011; Rosado et al., 2011), including UVents, including those that limit nucleotide incorporation into
ogression (e.g., camptothecin and platinum drugs). Replica-
thway and cause genomic instability in cells lacking pathway
/BRCA pathway in protecting stalled replication forks from
tanding of expanded roles of these tumor suppressors with
tanding tumor susceptibility in patients with FA, therapeutic
Figure 1. FA/BRCA Gene Network Protects Stalled DNA Replication Forks
(A) A graphical representation of the FA/BRCA gene network depicts FA core complex proteins (FANCA, B, C, E, F, G, L, M), which promote the mono-
ubiquitination (Ub) of FANCD2 and FANCI. BRCA-related proteins (FANCD1/BRCA2, FANCN/PALB2, and FANCJ/BRIP1) and recently identified FANCO/
RAD51C and FANCP/SLX4 are not required for FANCD2–FANCI monoubiquitination and act downstream or in parallel to canonical FA proteins. While BRCA1 is
part of the FA/BRCA gene network, BRCA1 mutations have not been found in FA patients. BLM interacts with the gene network, but its loss causes a distinct
syndrome.
(B) Graphical sketch of experimental design of fork protection assay. Lengths of nascent replication tracts (labeled with IdU) aremeasured byDNA spreading after
5 hr of replication stalling with HU. Representative DNA fiber images are given. Scale bars (white) correspond to 4 mm.
(C) Preformed IdU tract lengths measuring replication fork stability by DNA spreading in patient-derived FANCD2-defective PD20 cells, but not cells
complemented with the wild-type protein, shorten with HU. Median IdU tract lengths are given in parentheses here and in subsequent figures.
(D) Nascent tract length distribution curve measured by DNA spreading in patient-derived FANCA-defective GM6914 cells show nascent strand shortening with
HU, unlike cells complemented with the wild-type protein.
(E) Nascent tract length distribution curve measured by DNA spreading in PD20 cells expressing the FANCD2 K561R mutant defective for monoubiquitination
show nascent strand shortening with HU.
See also Figure S1.
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FA/BRCA Pathway Prevents Stalled Fork Instabilitydamage, which primarily is removed by other repair pathways.
Moreover, FANCD2 functionally interacts with the RAD51-
mediator protein BRCA2 (Hussain et al., 2004; Wang et al.,
2004). However, FA proteins are not canonical HR factors, as
cells derived from FA patients are not severely defective in HR
repair of double-strand breaks (Nakanishi et al., 2011). Thus,
the functional relationship between FA and HR proteins during
replication stalling remains enigmatic. The importance of replica-
tion stalling to tumor development is underscored by the obser-vation that oncogene activation in general induces replication
stress (Bartkova et al., 2006), and specifically by the recent
finding that precancerous oncogene expression reduces nucle-
otide pools (Bester et al., 2011).
To address general roles of FA/BRCA proteins during per-
turbed replication and to provide a more accurate and complete
appreciation of how these proteins function in replication fork
fidelity with implications for therapeutic strategies, we examined
the functional connection between FANCD2 and HR proteins atCancer Cell 22, 106–116, July 10, 2012 ª2012 Elsevier Inc. 107
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FA/BRCA Pathway Prevents Stalled Fork Instabilityreplication forks stalled by nucleotide depletion with HU as well
as replication stalling chemotherapeutic agents.
RESULTS
Fanconi Anemia Proteins Protect Stalled DNA
Replication Forks
BRCA2 and RAD51 can act in replication fork stabilization inde-
pendent of double-strand break repair (Hashimoto et al., 2010;
Lomonosov et al., 2003; Schlacher et al., 2011). Specifically,
RAD51 recombinase filament stabilization by the BRCA2 C
terminus (C-ter) protects against nucleolytic degradation of
stalled replication forks. Stalled replication forks that are not pro-
tected by BRCA2 lead to chromosomal instability. We reasoned
that if this distinct mechanism is involved in disease suppression,
defects may be found associated with disease susceptibility
genes other than BRCA2. Because BRCA2 is a suppressor of
FA and as such is also known as FANCD1, we tested a possible
function for FA genes in fork stability. Specifically, nascent repli-
cation tracts were IdU-labeled before replication stalling with
hydroxyurea (HU) (Figure 1B); the retention of the label after
HU treatment serves as a measure for fork stability using DNA
fiber spreading (Schlacher et al., 2011).
To test an involvement of FAproteins in protecting stalled repli-
cation forks, we monitored the stability of nascent replication
tracts in FA patient-derived cells defective in FANCD2. Replica-
tion stalling causes a dramatic shortening of themedian IdU tract
length in FANCD2-defective PD20 cells compared either tomock
treatment (Figure 1C, 4.18 mmand 8.12 mm, p< 0.0001) or to cells
complemented with FANCD2 (Figure 1C, 8.08 mm and 8.32 mm,
p = 0.2735). These results with FANCD2-defective cells are
similar to those obtained with BRCA2 (FANCD1)-defective
patient cells (Figure S1 available online) and with BRCA2-
defective rodent cells (Schlacher et al., 2011).
FA pathway activation involves monoubiquitination of the
FANCD2/FANCI proteins by FA core complex proteins
(D’Andrea, 2010). Similar to FANCD2-defective cells, we found
that patient-derived GM6914 cells defective in the core complex
protein FANCA show degradation of newly synthesized DNA
strands when treated with HU, but not with mock treatment (Fig-
ure 1D, 4.15 mm and 7.85 mm, p < 0.0001). Yet nascent strands
are maintained intact in FANCA-complemented cells (Figure 1D,
8.37 mm and 8.26 mm, p = 0.3702). This suggests a functional
requirement for FA proteins upstream of FANCD2 monoubiquiti-
nation in maintaining fork stability.
To directly assess if fork protection requires FA pathway acti-
vation by monoubiquitination of FANCD2, we analyzed nascent
replication tracts in PD20 cells expressing mutant FANCD2-
K561R incapable of being ubiquitinated (Ub) (Garcia-Higuera
et al., 2001).We found that these cells fail tomaintain the integrity
of nascent DNA tracts during replication stalling with HU (Fig-
ure 1E, 4.89 mm and 9.44 mm, p < 0.0001). Thus, in addition to
BRCA2, fork stabilization requires FA pathway activation through
FANCD2 monoubiquitination.
FA Pathway Suppresses Genomic Instability When
Replication Is Stalled
We tested the cellular consequence of replication stalling by
nucleotide depletion on FA-defective cells. Metaphase spreads108 Cancer Cell 22, 106–116, July 10, 2012 ª2012 Elsevier Inc.of FANCA-defective GM6914 cells show significantly elevated
levels of spontaneous chromosomal aberrations compared to
cells that are complemented with wild-type FANCA (Figure 2A,
p = 0.0107). Upon treatment with HU, the load of DNA breaks
and radial structures in GM6914 cells considerably increases
from an average of 0.6 to 2.5 aberrations per cell (Figure 2A,
p < 0.0001), while only a moderate elevation is observed in
FANCA-complemented cells from 0.34 to 0.72 aberrations per
cell (Figure 2A, p = 0.0836). Thus, replication stalling by nucleo-
tide depletion selectively elevates genomic instability in FA-
defective cells.
Genomic instability upon HU, however, is not accompanied
by acute cell death. While FANCA-defective cells are exquisitely
sensitive to ICL-inducing reagents such as mitomycin-C (MMC,
Figure S2A), they show no substantial difference in cellular
survival rates compared to FANCA-proficient cells upon treat-
ment with HU (Figure 2B). Interestingly, when we tested
BRCA2/FANCD1-defective cells for MMC sensitivity, we found
that cells containing the BRCA2 S3291A variant, which is profi-
cient for double-strand break repair but cannot protect stalled
forks, shows only moderate sensitivity to high concentrations
of MMC compared to cells with BRCA2 truncation (Figure S2B),
suggesting two separable functions for BRCA2/FANCD1 during
ICL repair, one of which involves replication fork protection.
Other replication stalling agents such as the chemotherapeu-
tics gemcitabine (Figure 2C), which inhibits replication elonga-
tion, or camptothecin (Figure S2C), a replication poison that
prevents DNA ligation and elicits a roadblock to replication by
covalently locking topoisomerase I to DNA, show similar results
compared to HU with no to very mild acute cellular death. These
results suggest that immediate cell death is not an obligate
immediate consequence of replication stalling in FA-defective
cells.
We next examined if FA proteins are required for fork protec-
tion when replication is stalled by agents other than HU. Replica-
tion tracts are maintained intact in FANCA-proficient cells when
treated with the chemotherapeutic gemcitabine (Figure 2D, p =
0.612 with and without gemcitabine). In contrast, the nascent
strands shorten dramatically in FANCA-defective GM6914 cells
with gemcitabine (Figure 2D, p < 0.0001). Likewise, exposure
to camptothecin shortens replication tracts in FA-defective cells
(Figure 2E, p < 0.0001). Thus, replication stalling caused by
various agents elicit fork instability in FANCA-defective cells.
Parallel and Downstream Functions of FA-Associated
Proteins
Several proteins have been identified to associate with FA
components, although they are not considered to be FA proteins
as mutations have not been found as yet in FA patients. The
BRCA1 breast cancer suppressor associates in complexes
with several FANC proteins, including FANCD2 and BRCA2
(Moldovan and D’Andrea, 2009). We found that BRCA1-defec-
tive mouse embryonic stem (ES) cells show shortened nascent
tracts with replication stalling (Figure 3A, 5.52 mm and 8.88 mm,
p < 0.0001), unlike cells with a functional BRCA1 (Figure 3A,
8.82 mm and 8.73 mm, p = 0.831). Thus, both BRCA1 and
BRCA2—the major hereditary breast cancer suppressors—
stabilize replication forks, providing a mechanistic link between
tumor suppression and the protection of stalled replication forks.
Figure 2. FA Pathway Suppresses Genomic Instability upon Replication Stalling
(A) Chromosomal aberrations measured by metaphase chromosome spreads with FANCA-deficient and –complemented GM6914 cells with HU (± SD, n = 40).
Representative images of chromosomal aberrations of metaphase chromosomes are given. Scale bars (gray) correspond to 2 mm.
(B) Cell survival analysis of FANCA-defective, patient-derived GM6914 cells and cells complemented with FANCA upon continuous HU treatment (± SEM, n = 4).
(C) Cell survival analysis of FANCA-defective cells and cells complemented with FANCA upon continuous gemcitabine (GEM) treatment (± SEM, n = 3).
(D and E) Nascent tract length distribution curves measured by DNA spreading in patient-derived FANCA-defective GM6914 cells and cells complemented with
the wild-type protein with gemcitabine [GEM, (D)] and camptothecin [CPT, (E)].
See also Figure S2.
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FA/BRCA Pathway Prevents Stalled Fork InstabilityBLM helicase interacts with both FA and BRCA networks
(Chu and Hickson, 2009; Deans and West, 2009; Moldovan
and D’Andrea, 2009). Loss of BLM causes Bloom syndrome,
a developmental disorder with high cancer predisposition (Chu
and Hickson, 2009), but is phenotypically distinct from FA. On
the cellular level, BLM, in partnership with TopIIIa, decatenates
fully replicated chromosomes (Chu and Hickson, 2009). We
used mouse ES cells expressing BLM under negative doxycy-
cline control (Figure 3B, Blmtet/tet inset) to assess if BLM playsa role in the protection of stalled forks from degradation. BLM-
depleted cells maintain IdU tracts intact when exposed to
HU (Figure 3B, Blmtet/tet+DOX; 7.93 mm and 7.72 mm, p =
0.338), similar to cells expressing BLM (Figure 3B, Blmtet/tet;
8.09 mm and 8.12 mm, p = 0.831). Thus, unlike BRCA and
FANC deficiency, loss of BLM does not result in degradation of
stalled replication forks.
BLM helicase, however, is required for efficient replication
restart after HU (Davies et al., 2007) (Figure S3A). Related toCancer Cell 22, 106–116, July 10, 2012 ª2012 Elsevier Inc. 109
Figure 3. Parallel and Downstream Functions of FA-Associated Proteins
(A) Replication fork stability analysis by DNA spreading of preformed IdU tracts in BRCA1-deficient mouse ES cells (mESBrca1/) andmouse ES cells containing
wild-type BRCA1 (mES Brca1+/) with HU. Median IdU tract lengths are given in parenthesis here and in subsequent graph panels.
(B) Replication fork stability analysis by DNA spreading of preformed IdU tracts in BLM-depleted mouse ES cells with negative doxycycline (DOX) control of BLM
expression (mES Blmtet/tet +DOX) and BLM proficient ES cells (mES Blmtet/tet). See inset, western blot for BLM expression.
(C) Replication recovery analysis after fork stalling with HU as measured by DNA spreading of CldU replication tracts in BLM-depleted (mES Blmtet/tet +DOX) and
BLM proficient mouse ES cells (mES Blmtet/tet). Median CldU tract lengths are given in parentheses here and in subsequent graph panel.
(D) Replication recovery analysis (CldU tract length) after fork stalling is in FANCD2-defective and in FANCD2-complemented PD20 cells.
See also Figure S3.
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FA/BRCA Pathway Prevents Stalled Fork Instabilitythis, we find that BLM-depleted cells have a defect in replication
recovery as measured by substantially shorter CldU tracts after
exposure to HU when compared with cells expressing wild-
type BLM (Figure 3C, 3.59 mm and 6.28 mm, p < 0.0001 and Fig-
ure S3B). Thus, BLM deficiency results in defects in replication
recovery that can be observed by measuring either the length
of the replication tracts (Figure 3C) or the frequency of forks
that restart (Davies et al., 2007; Figure S3A).
Because BLM interacts with both FA and BRCA networks, we
further tested FA (Figure 3D and Figure S3C) and BRCA1-defec-110 Cancer Cell 22, 106–116, July 10, 2012 ª2012 Elsevier Inc.tive cells (Figure S3D) for replication recovery after stalling with
HU. Similar to BRCA2 deficiency (Schlacher et al., 2011) but in
contrast to BLM deficiency (Figure 3C), no defect in replication
recovery is observed: replication tracts formed after HU are simi-
larly short in both FANCD2-defective and -complemented PD20
cells after exposure to HU (Figure 3, 4.12 mm and 3.73 mm, p =
0.0029 and Figure S3E). Similar results were obtained for FANCA
(Figures S3C and S3F) and BRCA1-defective cells (Figures S3D
and S3G). These data suggest that BLM acts downstream of the
BRCA and FANC proteins, subsequent to the protection of
Figure 4. FA Genes Protect Against MRE11-Dependent Fork Degradation
(A) Replication fork stability analysis by DNA spreading of IdU replication tracts in FANCD2-deficient PD20 cells during various exposure times to HU. Inset; the
rate of IdU tract length change is 0.87 mm/hr, estimated to be 2.2 kb/hr.
(B) Replication fork stability analysis by DNA spreading of IdU replication tracts in FANCD2-deficient PD20 with chemical inhibition of MRE11 nuclease by
treatment with mirin, with and without HU.
See also Figure S4.
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FA/BRCA Pathway Prevents Stalled Fork Instabilitystalled forks, perhaps in decatenation of structures elicited by
positive supercoiling ahead of the fork.
FA Genes Protect Against MRE11-Dependent Fork
Degradation
MRE11 nuclease promotes degradation of stalled replication
forks when either BRCA2 or RAD51 function is impaired (Hashi-
moto et al., 2010; Schlacher et al., 2011). We found that degra-
dation in FANCD2-defective cells occurs at 2.2 kb/hr (Fig-
ure 4A, inset), which is reminiscent of the slow kinetics of
MRE11-dependent degradation in BRCA2-defective cells
(Schlacher et al., 2011). Moreover, double-labeling experiments
suggest that both leading and lagging strand degradation
occurs, as the most recently incorporated nucleotides are
excised first (Figures S4A–S4C). These results suggest that
MRE11 nuclease, which promotes both 30–50 and 50–30 end pro-
cessing (Williams et al., 2008), mediates the nascent replication
tract shortening in FA-defective cells. We chemically inhibited
MRE11 nuclease with mirin (Dupre´ et al., 2008), and found that
it blocks nascent tract shortening upon fork stalling with HU (Fig-
ure 4B, 16.46 mm and 16.59 mm, p = 0.738). Therefore, FANCD2,
like BRCA2 andRAD51, protects nascent strands at stalled repli-
cation forks from degradation by MRE11.
Functional Interaction of FA and RAD51 Proteins at
Stalled Forks
RAD51 was recently shown to act downstream of FANCD2
during ICL repair (Long et al., 2011). Yet, RAD51 is recruited to
ICLs prior to FANCD2 such that a second function upstream of
ICL incision could not be excluded (Long et al., 2011). We there-
fore sought to address whether FANCD2 acts in synergy with
RAD51 when protecting stalled forks or whether they act epis-
tatically, within a common pathway. To test this, we expressedthe BRC4 peptide (Saeki et al., 2006), which suppresses DNA
binding of RAD51 and thus disrupts RAD51 filaments.
Replication tracts are dramatically shortened upon HU
in FANCD2-complemented PD20 cells expressing the BRC4
peptide (Figure 5A, 3.86 mm and 8.18 mm p < 0.0001), demon-
strating efficient RAD51 depletion from filaments leading to
fork destabilization. Moreover, RAD51 depletion in PD20 cells
complemented with FANCD2 mimics the replication tract short-
ening seen with deficiency of FANCD2 itself (compare Figure 5A,
3.86 mm, and Figure 5B, 4.17 mm, p = 0.104). Although replication
tracts are significantly shorter in FANCD2-defective cells with
HU compared to without HU (Figure 5B, 4.17 mm and 8.9 mm,
p < 0.0001), the tract shortening is not exacerbated by depletion
of RAD51 from filaments (Figure 5B, 4.11 mm, p = 0.324). Taken
together, the data suggest that RAD51 and BRCA2 act in epis-
tasis with FANCD2 for replication fork stabilization.
Given that perturbing RAD51 in FANCD2-defective cells
results in a phenotype comparable to FANCD2 deficiency alone,
we hypothesized that FANCD2 may play a role in RAD51 fila-
ment stabilization subsequent to RAD51 loading onto DNA. To
gain insight into the mechanism of FANCD2-mediated fork
stabilization, we expressed the RAD51 K133R mutant. This
mutant is devoid of ATPase activity required for dissociation
from DNA (Morrison et al., 1999), and thus forms hyperstable
filaments. We found that RAD51 K133R renders IdU tracts
in PD20 cells resistant to degradation, maintaining replication
tract lengths comparable to those observed in PD20 cells ex-
pressing wild-type FANCD2 (compare Figure 5C, 7.95 mm, and
Figure 5A, 8.18 mm, p = 0.825). Thus, fork instability caused by
FANCD2 deficiency can be compensated for by RAD51 filament
stabilization.
Elevated RAD51 protein levels are often found in tumor
cells (Raderschall et al., 2002b; Brown and Holt, 2009), whichCancer Cell 22, 106–116, July 10, 2012 ª2012 Elsevier Inc. 111
Figure 5. Functional Interaction of FA and RAD51 Proteins at Stalled Forks
(A) Replication fork stability analysis by DNA spreading of IdU replication tracts in FANCD2-complemented PD20 cells expressing flag-tagged BRC4-peptide (see
western blot, inset), which disrupts RAD51 binding to DNA.
(B) Replication fork stability analysis by DNA spreading of IdU replication tracts in FANCD2-deficient PD20 cells expressing flag-tagged BRC4-peptide (see
western blot, inset).
(C) Replication fork stability analysis by DNA spreading of IdU replication tracts in FANCD2-deficient PD20 cells expressing mutant RAD51 K133R (see western
blot, inset), which forms stable filaments, upon fork stalling with HU.
(D) Replication fork stability analysis by DNA spreading of IdU replication tracts in FANCD2-deficient PD20 cells overexpressing wild-type (WT) RAD51 (see
western blot, inset), which promotes filament assembly, upon fork stalling with HU.
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FA/BRCA Pathway Prevents Stalled Fork Instabilityperhaps drives more stable filament formation (Raderschall
et al., 2002a), suggesting the potential for even wild-type
RAD51 to effect fork protection. We therefore examined the
effect of higher levels of wild-type RAD51 on replication tract
stability in FA-defective cells. Strikingly, we found that overex-
pression of wild-type RAD51 in FANCD2-defective PD20 cells112 Cancer Cell 22, 106–116, July 10, 2012 ª2012 Elsevier Inc.can partially rescue replication fork instability upon HU and
primarily maintain replication tracts intact (Figure 5D, 4.17 and
6.50 without and with increased RAD51 expression, p <
0.0001). Taken together, the data show that FANCD2 and
RAD51 support each other at replication forks such that both
FANCD2 andRAD51 positively regulate replication tract stability.
Figure 6. Model of FA/BRCAGene Network Functions in Replication
Fork Stability
Nucleotide depletion, as caused by oncogene activation or chemotherapeutic
agents, stalls replication forks. FA/BRCA proteins stabilize RAD51 at stalled
replication forks to protect nascent strands from MRE11-dependent degra-
dation. RAD51 filament stabilization in the absence of FA/BRCA proteins is
sufficient for fork protection. This can be achieved by gain of function mutant
RAD51 or overexpression of wild-type RAD51, as commonly seen in tumor
cells. BLM-TopIIIa acts downstream in the restart of stalled forks. Protein
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Because of the exquisite sensitivity of FA genes to ICL lesions,
most studies thus far have focused on their role in ICL repair.
Yet, the FA machinery prevents genome instability and lethality
caused by replication blocks other than ICLs with uncharacter-
ized implications for tumorigenesis (Howlett et al., 2005; Lan-
gevin et al., 2011; Naim and Rosselli, 2009; Rosado et al.,
2011). Here the discovery of a role for FANCD2-Ub in preventing
degradation of nascent DNA strands in vivo independent of ICL
processing complements and extends existing results. Notably,
FANCD2-Ub functions epistatically with RAD51 at stalled forks
within this distinct pathway, as does BRCA2, which provides
a more complete understanding of how these proteins maintain
replication fork fidelity in the context of ICL and other DNA
stresses.
FANCD2 monoubiquitination involves an interaction with the
replisome component proliferating cell nuclear antigen (PCNA)
(Howlett et al., 2009). Because BRCA2/RAD51 functionally inter-
acts with FANCD2 (Long et al., 2011; Wang et al., 2004) and
BRCA2/RAD51 alone is insufficient for fork protection in the
absence of FANCD2-Ub, a testable mechanistic model is that
as part of a protein supercomplex FANCD2-Ub connects the
BRCA and RAD51 proteins to replisome components to stabilize
stalled forks and prevent fork collapse (Figure 6). This protection
mechanism provides a functional explanation for the observa-
tions that upon replication stalling both BRCA1 and BRCA2
rapidly relocalize to replication foci containing PCNA (Chen
et al., 1998). Moreover, FANCD2 colocalizes with PCNA and
RAD51 to foci in response to HU (Hussain et al., 2004) and
FANCD2 is found localized to sister chromatids upon replication
stress (Naim and Rosselli, 2009). It recently was reported that an
FA component stabilizes a specialized translesion synthesis
(TLS) DNA polymerase at nuclear foci upon DNA damage (Kim
et al., 2012). Thus, given the data and model presented here, it
will be interesting to see if this polymerase stabilizing function
could hold true for other DNA polymerases and in particular non-
specialized polymerases, because TLS polymerases are unlikely
to be involved when replication is stalled without eliciting DNA
lesions such as by HU.
Other FA proteins may be found to act in this distinct pathway
of fork stabilization. FANCJ is important in processing DNA
secondary structures at G-rich regions (Hiom, 2010). In the
context of replication fork stability, disruption of such G-rich
structures may be crucial to create single-strand DNA stretches
long enough to support sufficiently stable RAD51 filaments.
FANCP (SLX4) binds to several endonucleases implicated in
ICL processing (Cybulski and Howlett, 2011). However, it is
feasible that FANCP (SLX4) may have additional functions that
support the structural maintenance of replication fork structures
through Smc5/6 (Ohouo and Smolka, 2011), as how Smc5/6
promotes chromosome stability is largely unknown and it
may have a role in the maintenance of undamaged chromo-
somes. Structural destabilization of replication forks and forkcolors: BRCA2, pink; FANCD2, green; ubiquitin, dark green; BRCA1, light
pink; wild-type RAD51, dark blue; RAD51 K133R, steel gray; PCNA, blue
(doughnut); MRE11 yellow (pacman). BLM-TopIIIa, scalpel.
See also Figure S5.
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FA/BRCA Pathway Prevents Stalled Fork Instabilitydegradation indeed provide feasible mechanisms for both spon-
taneous fork breakage and deletion mutations, both of which
are hallmarks of FA-defective cells (Papadopoulo et al., 1990;
Schroeder et al., 1964).
FA is a disease with life-threatening consequences on hema-
topoiesis, marked by stem cell attrition before the development
of tumors. Consistent with a nonlethal phenotype during em-
bryogenesis and the small stature of FA patients, we find that
replication stalling does not elicit acute but only marginal cell
death in FA-defective cells (Figure 2B). Yet, unprotected replica-
tion forks result in DNA damage as indicated by the marked
increase in genomic aberrations in FA-defective cells upon treat-
ment with HU (Figure 2A). As DNA damage has recently been
shown to promote hematopoietic stem cell aging (Wang et al.,
2012), we propose in particular that nonlethal DNA damage
may promote hematopoietic stem cell attrition by accumulated
differentiation rather than cell death. Nonlethal DNA damage in
other tissues on the other hand could eventually promote tumor-
igensis by prolonged cellular exposure to mutagenesis without
cell death and account for the high tumor susceptibility in FA
patients. Thus, replication fork protection potentially provides a
mechanism to resolve the apparent paradox involving the seem-
ingly opposing phenotypes of stem cell death and mutagenesis
promoting tumor predisposition.
Fork stabilization is likely also an important event during ICL
repair, consistent with data demonstrating RAD51 recruitment
to stalled forks before ICL processing (Long et al., 2011). Our
observation that a variant of BRCA2/FANCD1 defective in fork
protection sensitizes cells to ICLs, however to a much lesser
extent than mutant BRCA2/FANCD1 defective in both DSB
repair and fork protection, suggests that both fork protection
and DSB repair contribute to the suppression of lethality upon
ICL. Intriguingly, a dual role during ICL repair beyond DSB repair
was also recently reported for BRCA1 (Bunting et al., 2012). The
fork protection role for BRCA1 that we report here could there-
fore be feasibly related to the DSB repair-independent function
of BRCA1 during ICL repair. Likewise, sensitivity of FA-deficient
cells to ICLs may involve fork protection. While FA proteins
clearly have separate roles during ICL repair (Knipscheer et al.,
2009; Kim et al., 2012), fork stabilization may not be essential
to ensure the complete removal of this lethal type of lesion.
Rather, we suggest that during ICL repair, fork stabilization by
BRCA and FA proteins may increase access for nucleases and
thus the efficiency for incision and subsequent repair.
However, replisome stalling is far more frequent than ICL
processes and has particular significance for rapidly cycling cells
such as cells of the hematological system or those responding to
mitogenic signals like hormones. Moreover, precancerous onco-
gene expression by HPV infection can induce replication stress
by decreasing nucleotide pools (Bester et al., 2011). This direct
connection between tumor initiation and replication stalling
together with our data showing that FA proteins suppress
genomic instability by protecting stalled forks suggests a mech-
anistic basis for the observed susceptibility of FA patients to oral
cancer upon HPV infection (Park et al., 2010). Protection and
stabilization of replication forks has critical implications for the
maintenance of genomic integrity and thus likely constitutes an
unanticipated mechanism of tumor suppression. In support of
this hypothesis, we identified the sporadic breast cancer cell114 Cancer Cell 22, 106–116, July 10, 2012 ª2012 Elsevier Inc.line MCF7 to be defective in protecting stalled forks (Figure S5),
which implies that this distinct mechanism is also linked to some
sporadic cancers.
Cancer therapeutics target DNA replication and dividing cells,
so that DNA damage responses are exploited as therapeutic
targets and resistance factors. Our experiments reveal that
RAD51 stabilization rescues FANCD2 deficiency in protecting
stalled forks, despite the fact that FA proteins are clearly not
canonical HR factors. This surprising result underscores the
emerging importance of an unappreciated aspect in RAD51 fila-
ment mediation, which differs from loading of RAD51 onto DNA
to promote strand exchange, to instead utilize RAD51 filaments
to stabilize DNA structures. Importantly, wild-type RAD51 is
often found overexpressed in tumors that acquired resistance
to chemotherapeutic drug treatment (Brown and Holt, 2009),
which is sufficient in overcoming genetic defects to restore repair
functions in these cells and, as we show here, also replication
fork stability to a large extent. While defects in replication fork
protection elicit genomic instability that initially contribute to
tumorigenesis, restoration of the function by RAD51 overexpres-
sion after transformation could benefit the proliferative capacity
of the tumor cell. Our results provide a mechanistic link between
tumor suppression and the protection of stalled replication forks
by showing that both BRCA1 and BRCA2, the major hereditary
breast cancer suppressors, stabilize replication forks. Thus,
our collective results unite breast cancer and FA susceptibility
genes in one common molecular process that protect against
genomic instability. This integrated function for the FA/BRCA
gene network in stabilizing stalled forks is expected to prompt
investigations of this distinct pathway in tumorigenesis, stem
cell aging and controlling stalled DNA replication processes to
suppress genomic instability that will shape emerging thera-
peutic strategies.
EXPERIMENTAL PROCEDURES
Cell Lines
SV40-transformed FA fibroblasts (GM6914, GM6914+FANCA, PD20F, and
PD20F+FANCD2 (Jakobs et al., 1996; Na¨f et al., 1998; Timmers et al., 2001)
were previously described and are also available through the FA Cell Reposi-
tory at Oregon Health & Science University. Mouse ES cells (Brca1/ and
Brca1+/ [Gowen et al., 1996; Moynahan et al., 1999]; Blmtet/tet [Yusa et al.,
2004]) were previously described.
Drugs
50 iodo-20deoxyuridine (IdU), 50chloro-20deoxyuridine (CldU), and HU were
purchased from Sigma-Aldrich. Mirin (Dupre´ et al., 2008) was provided by
the MSKCC Organic Synthesis Core Facility.
Cell Transfection
Using Fugene 6 (Roche Applied Science) and following the manufacturer’s
instructions, 105 PD20 or complemented cells were transfected with 2 mg of
flag-BRC4, RAD51 K133R, wild-type RAD51 or empty (pCaggs) expression
plasmids. Expression of the peptides was tested 40 hr post transfection by
standard western blotting using Anti-Flag Clone M2 (Sigma-Aldrich) antibody
against flag-BRC4 or anti-RAD51 antibody (Santa Cruz) against RAD51 K133R
or wild-type RAD51.
DNA Fiber Spreads
DNA fiber spreads were prepared as previously described (Schlacher et al.,
2011). Briefly, replication tracts of log-phase cells were pulse labeled with
50 mM IdU and CldU before or after replication stalling with 4 mM HU, 1 mM
Cancer Cell
FA/BRCA Pathway Prevents Stalled Fork Instabilitygemcitabine or 0.5 mM camptothecin respectively, as indicated in the
sketches. Cells were harvested, lysed and spread to obtain single DNA mole-
cules on microscope slides before standard immunofluorescence with anti-
bodies against IdU and CldU (Novus Biologicals, BD Biosciences).
Statistical Analysis
Between 100 and 1400 nascent DNA tracts were measured using ImageJ
software from 1-3 independent experiments. P-values obtained from the
Mann-Whitney test and the 95% confidence intervals were calculated using
Prism software.
Cellular Survival Assays
For survival assays, 3000 cells were seeded in a 24-well plate the day before
continuous treatment with the indicated drugs. The number of viable cells
was determined when confluency reached80% for the untreated cells using
Cell Titer 96 AQueous One Solution Cell Proliferation Assay (Promega).
Metaphase Spread Analysis
For metaphase spreads, 2 3 105 cells were seeded the day before HU treat-
ment (4 mM) and treated with colcemid (0.1 mg/ml, GIBCO), as indicated.
For metaphase spreads, cells were swollen with 0.075 M KCL (12 min,
37C), fixed with methanol/acetic acid (3:1), dropped onto a microscope slide,
stained with 5% Giemsa, and mounted with Cytoseal 60 (Fisher Scientific)
before imaging with an Olympus BX60 microscope.
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